troglitazone has been researched along with Cancer of the Tongue in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshida, K | 1 |
| Hirose, Y | 1 |
| Tanaka, T | 1 |
| Yamada, Y | 1 |
| Kuno, T | 1 |
| Kohno, H | 1 |
| Katayama, M | 1 |
| Qiao, Z | 1 |
| Sakata, K | 1 |
| Sugie, S | 1 |
| Shibata, T | 1 |
| Mori, H | 1 |
1 other study available for troglitazone and Cancer of the Tongue
| Article | Year |
|---|---|
Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide.
Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Agents; Bromodeoxyuridine; Carcinogens; Chromans; | 2003 |